Head-To-Head Comparison: Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for Brainstorm Cell Therapeutics and Protara Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0	0	1	0	3.00
Protara Therapeutics	0	0	5	0	3.00

Brainstorm Cell Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 1,798.73%. Protara Therapeutics has a consensus price target of $22.50, suggesting a potential upside of 409.05%. Given Brainstorm Cell Therapeutics’ higher probable upside, equities research analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Protara Therapeutics.

Profitability

This table compares Brainstorm Cell Therapeutics and Protara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-528.56%
Protara Therapeutics	N/A	-55.96%	-49.06%

Institutional and Insider Ownership

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Brainstorm Cell Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

Earnings and Valuation

This table compares Brainstorm Cell Therapeutics and Protara Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$17.19 million	($4.80)	-0.33
Protara Therapeutics	N/A	N/A	-$40.42 million	($2.40)	-1.84

Protara Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protara Therapeutics beats Brainstorm Cell Therapeutics on 6 of the 10 factors compared between the two stocks.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.